<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: There is great interest in whether type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and its treatments alter <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk and prognosis, but previous studies are inconclusive </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted a cohort study within the UK General Practice Research Database to investigate associations of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and patterns of <z:mp ids='MP_0002055'>diabetes</z:mp> treatment with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk and <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We identified 52,657 women with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, diagnosed between 1987 and 2007, and 30,210 randomly selected women without <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>We performed a time-dependent analysis using Cox proportional hazards models </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:mp ids='MP_0002055'>Diabetes</z:mp> was associated with a 29 % increased overall <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk (95 % CI: 1.16-1.44), but the association markedly attenuated when adjusted for age, period of cohort entry, region, and body mass index (BMI) (HR: 1.12; 95 % CI: 0.98-1.29) </plain></SENT>
<SENT sid="5" pm="."><plain>Women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and pre-existing <z:mp ids='MP_0002055'>diabetes</z:mp> had a 49 % (95 % CI: 1.17-1.88) increased <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality risk compared with women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> but without <z:mp ids='MP_0002055'>diabetes</z:mp>, after controlling for age, period, region, BMI, smoking, alcohol, and deprivation </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi>, we found weak evidence that <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy (HR: 1.04; 95 % CI: 0.79-1.37) and insulin (HR: 1.33; 95 % CI: 0.63-2.83) modified <z:hpo ids='HP_0003002'>breast cancer</z:hpo> risk among women with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: We found weak evidence that <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with a small increased risk of <z:hpo ids='HP_0003002'>breast cancer</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Among treated women, there is no evidence that anti-<z:mp ids='MP_0002055'>diabetes</z:mp> treatments modify the risk of developing <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, with wide confidence intervals indicating imprecise effect estimates </plain></SENT>
<SENT sid="9" pm="."><plain>Women with <z:hpo ids='HP_0003002'>breast cancer</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp>, however, had an increased <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality risk highlighting the potential importance of maintaining adequate glycemic control alongside anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatments and subsequent follow-up </plain></SENT>
</text></document>